What are Analysts opinions on: AbbVie Inc. (NYSE:ABBV)


AbbVie Inc. (NYSE:ABBV) will report its next earnings on Jan 27 – Jan 31 (Est.). The company reported the earnings of $1.21/Share in the last quarter where the estimated EPS by analysts was $1.2/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 0.8%.

Many analysts are providing their Estimated Earnings analysis for AbbVie Inc. and for the current quarter 18 analysts have projected that the stock could give an Average Earnings estimate of $1.19/share. These analysts have also projected a Low Estimate of $1.17/share and a High Estimate of $1.26/share.

In case of Revenue Estimates, 15 analysts have provided their consensus Average Revenue Estimates for AbbVie Inc. as 6.91 Billion. According to these analysts, the Low Revenue Estimate for AbbVie Inc. is 6.64 Billion and the High Revenue Estimate is 7.15 Billion. The company had Year Ago Sales of 6.36 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for ABBV to be 5.3%. They are projecting Next Quarter growth of 8.7%. For the next 5 years, AbbVie Inc. is expecting Growth of 14.95% per annum, whereas in the past 5 years the growth was 18.57% per annum.

Some buy side analysts are also providing their Analysis on AbbVie Inc., where 4 analysts have rated the stock as Strong buy, 6 analysts have given a Buy signal, 11 said it’s a HOLD, 1 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 20 Analysts reported that the Price Target for AbbVie Inc. might touch $90 high while the Average Price Target and Low price Target is $70 and $49 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. AbbVie Inc. got Downgrade on 31-Oct-16 where investment firm Credit Suisse Downgrade the stock from Outperform to Neutral.

AbbVie Inc. closed its last trading session at $59.46 with the gain of 3.58%. The Market Capitalization of the company stands at 100.09 Billion. The Company has 52-week high of $68.12 and 52-week low of $50.71. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 2.86% where SMA50 and SMA200 are 0.67% and 1.85% respectively. The Company Touched its 52-Week High on Aug 15, 2016 and 52-Week Low on Jan 14, 2016.

The Relative Volume of the company is 1.64 and Average Volume (3 months) is 7.22 million. AbbVie Inc. P/E (price to earnings) ratio is 16.57 and Forward P/E ratio of 11.21.

The company shows its Return on Assets (ROA) value of 10.1%. The Return on Equity (ROE) value stands at 117.5%. While it’s Return on Investment (ROI) value is 16.9%.

While looking at the Stock’s Performance, AbbVie Inc. currently shows a Weekly Performance of 1.94%, where Monthly Performance is 6.93%, Quarterly performance is -3.12%, 6 Months performance is -0.2% and yearly performance percentage is 10.01%. Year to Date performance value (YTD perf) value is 7.99%. The Stock currently has a Weekly Volatility of 2.79% and Monthly Volatility of 2.84%.